BridgeBio Pharma (NASDAQ:BBIO)’s stock price traded up 0.3% on Tuesday . The company traded as high as $31.60 and last traded at $31.23, 6,627 shares changed hands during trading. A decline of 97% from the average session volume of 236,952 shares. The stock had previously closed at $31.14.
BBIO has been the subject of several research reports. UBS Group began coverage on shares of BridgeBio Pharma in a report on Tuesday. They issued a “reduce” rating for the company. Piper Jaffray Companies dropped coverage on BridgeBio Pharma in a research note on Friday, October 18th. Finally, Zacks Investment Research upgraded BridgeBio Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. BridgeBio Pharma has an average rating of “Buy” and an average target price of $40.13.
The company has a quick ratio of 14.00, a current ratio of 14.00 and a debt-to-equity ratio of 0.14. The firm has a fifty day simple moving average of $24.73.
Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in BridgeBio Pharma during the second quarter worth $476,000. Janus Henderson Group PLC purchased a new position in shares of BridgeBio Pharma in the second quarter valued at $9,331,000. TimesSquare Capital Management LLC purchased a new stake in BridgeBio Pharma during the 2nd quarter worth $4,046,000. JPMorgan Chase & Co. acquired a new position in BridgeBio Pharma in the 2nd quarter worth $25,274,000. Finally, Monashee Investment Management LLC purchased a new position in BridgeBio Pharma in the 2nd quarter valued at about $1,349,000. 83.46% of the stock is owned by institutional investors and hedge funds.
About BridgeBio Pharma (NASDAQ:BBIO)
BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
Further Reading: What is total return in investing?
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.